DCVMN is pleased to share that our CEO, Rajinder Suri, took part in the i-MCM-Net Partners Meeting from 17-19 September 2024 in Geneva.Β The i-MCM-Net, established and steeredΒ by the World Health Organization, focuses on ensuring readiness for potential pandemic preparedness and response to strengthening equitable access to medical countermeasures (MCM) during public health emergencies of international concern (PHEIC).
Rajinder Suri actively contributed to ππ°πΆπ―π₯ ππ’π£ππ¦ 2: ππ€π’ππ’π£ππ¦ ππ’π―πΆπ§π’π€π΅πΆπ³πͺπ―π¨, which explored key strategies for scaling up MCM manufacturing, particularly in low- and middle-income countries (LMICs). The session, chaired by Dr. Jicui Dong, Head of WHO’s Local Production and Assistance Unit, highlighted:
πΈ Adaptable manufacturing platforms
πΉ Geo-diversification of production with pre-negotiated agreements
πΈ “Ever-ready” production capabilities
πΉ Strengthened regulatory frameworks
During his presentation, Mr. Suri brought attention to the crucial role of developing country vaccine manufacturers (DCVMs) in ensuring scalable production and equitable access to vaccines and countermeasures. These interventions will boost the scheduling of an interactive meeting between DCVMN members and the WHO in the near future to take these steps forward, especially for Mpox.
DCVMN remains committed to enhancing global preparedness and response as well as supporting the production of vaccines that address the worldβs most pressing public health challenges.
